Deubiquitylating enzyme USP9x regulates radiosensitivity in glioblastoma cells by Mcl-1-dependent and -independent mechanisms

Cell Death and Disease

Volumn 7, Issue , 2016, Pages e2039-

  Wolfsperger, F ^a   Hogh Binder, S A ^a   Schittenhelm, J ^a   Psaras, T ^a   Ritter, V ^b   Bornes, L ^b   Huber, S M ^a   Jendrossek, V ^b   Rudner, J ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BIM PROTEIN; DEUBIQUITINASE; POLYUBIQUITIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; SMALL INTERFERING RNA; UBIQUITIN SPECIFIC PROTEASE 9X; UNCLASSIFIED DRUG; UBIQUITIN THIOLESTERASE; USP9X PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; ASTROCYTOMA; CELL SURVIVAL; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; ENZYME DEGRADATION; GLIOBLASTOMA; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; BRAIN TUMOR; FEMALE; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; PATHOLOGY; RADIATION TOLERANCE; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; RADIATION TOLERANCE; TRANSFECTION; UBIQUITIN THIOLESTERASE;

EID: 84955117020     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.405     Document Type: Article

References (44)

1. Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-Wienhues A et al. Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene 2000; 19: 1181-1190.
2. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
3. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
4. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011; 18: 1414-1424.
5. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008; 27: 6646-6656.
6. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
7. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
8. Huber S, Oelsner M, Decker T, zum Buschenfelde CM, Wagner M, Lutzny G et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011; 25: 838-847.
9. Trivigno D, Essmann F, Huber SM, Rudner J. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia 2012; 14: 893-904.
10. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006; 21: 749-760.
11. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-109.
12. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463: 103-107.
13. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880.
14. Tagscherer KE, Fassl A, Sinkovic T, Combs SE, Roth W. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737. Apoptosis 2012; 17: 187-199.
15. Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther 2011; 10: 1264-1275.
16. Peddaboina C, Jupiter D, Fletcher S, Yap JL, Rai A, Tobin RP et al. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer 2012; 12: 541.
17. Gratas C, Sery Q, Rabe M, Oliver L, Vallette FM. Bak and Mcl-1 are essential for temozolomide induced cell death in human glioma. Oncotarget 2014; 5: 2428-2435.
18. Murphy AC, Weyhenmeyer B, Noonan J, Kilbride SM, Schimansky S, Loh KP et al. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis 2014; 19: 629-642.
19. Allen JC, Talab F, Zuzel M, Lin K, Slupsky JR. c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. Blood 2011; 117: 2414-2422.
20. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007; 27: 4006-4017.
21. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-114.
22. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121: 1085-1095.
23. Wang B, Xie M, Li R, Owonikoko TK, Ramalingam SS, Khuri FR et al. Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. Cell Death Differ 2014; 21: 1160-1169.
24. Cox JL, Wilder PJ, Gilmore JM, Wuebben EL, Washburn MP, Rizzino A. The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PloS One 2013; 8: e62857.
25. Stegeman S, Jolly LA, Premarathne S, Gecz J, Richards LJ, Mackay-Sim A et al. Loss of Usp9x disrupts cortical architecture, hippocampal development and TGFbeta-mediated axonogenesis. PloS One 2013; 8: e68287.
26. Homan CC, Kumar R, Nguyen LS, Haan E, Raymond FL, Abidi F et al. Mutations in USP9X are associated with X-linked intellectual disability and disrupt neuronal cell migration and growth. Am J Hum Genet 2014; 94: 470-478.
27. Mouchantaf R, Azakir BA, McPherson PS, Millard SM, Wood SA, Angers A. The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X. J Biol Chem 2006; 281: 38738-38747.
28. Taya S, Yamamoto T, Kanai-Azuma M, Wood SA, Kaibuchi K. The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin. Genes Cells 1999; 4: 757-767.
29. Watson RL, Spalding AC, Zielske SP, Morgan M, Kim AC, Bommer GT et al. GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. Neoplasia 2010; 12: 357-365.
30. Azakir BA, Angers A. Reciprocal regulation of the ubiquitin ligase Itch and the epidermal growth factor receptor signaling. Cell Signal 2009; 21: 1326-1336.
31. Fedrigo CA, Grivicich I, Schunemann DP, Chemale IM, dos Santos D, Jacovas T et al. Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr. Radiat Oncol 2011; 6: 156.
32. Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J et al. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev 2014; 28: 1429-1444.
33. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J et al. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 1997; 150: 805-814.
34. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6: e1590.
35. Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, Ross AH et al. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD. Mol Cancer Res 2014; 12: 987-1001.
36. Levesley J, Steele L, Taylor C, Sinha P, Lawler SE. ABT-263 enhances sensitivity to metformin and 2-deoxyglucose in pediatric glioma by promoting apoptotic cell death. PloS One 2013; 8: e64051.
37. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
38. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
39. Chen HC, Kanai M, Inoue-Yamauchi A, Tu HC, Huang Y, Ren D et al. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat Cell Biol 2015; 17: 1270-1281.
40. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
41. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053-1058.
42. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiationinduced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
43. England B, Huang T, Karsy M. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 2013; 34: 2063-2074.
44. Ontikatze T, Rudner J, Handrick R, Belka C, Jendrossek V. Dihydroartemisinin is a hypoxiaactive anti-cancer drug in colorectal carcinoma cells. Front Oncol 2014; 4: 116.